Furthermore, a temperature pushover analysis (non linear static analysis for positive and negative temperature variations) is carried out to assess the failure pattern of the bridge caused by a temperature change, considered as one of the key parameters in IAB design.
This has also been included in iAB-RBC-283.
Another major expansion in metabolic capabilities represented in iAB-RBC-283 is lipid metabolism.
We also cross-referenced the enzymes in iAB-RBC-283 with the DrugBank's known protein targets of pharmaceuticals.
The finding of Mcp revertants with rearrangement breakpoints in iab-5 confirmed the assumption that the deletion affected iab-5 regulation (Karch et al. 1985).
It was, therefore, thought that the deletion caused misexpression of iab-5 in A4, perhaps by removing a repressor involved in iab-5 repression in segments anterior to A5.
Revertants of Fab-7 1 mapping further to the left in iab-5 or iab-4 were never recovered, indicating that iab-6 worked in an autonomous fashion with respect to the Fab-7 1 phenotype.
To determine potential uses, we cross-referenced the enzymes in iAB-RBC-283 with known morbid SNPs and enzymes that are reported drug targets in DrugBank.
Next, we showed that switching the iab-6 initiator with that of iab-5 caused the enhancers present in iab-6 to become active one parasegment too anterior, in PS10(A5).
The enzyme names in iAB-RBC-283 were cross-referenced against the database entries to determine morbid SNPs in erythrocyte proteins and drugs with protein targets in the erythrocyte.
